共 50 条
- [1] Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4107 - +O'Donnell, Peter H.Milowsky, Matthew I.Petrylak, Daniel P.Hoimes, Christopher J.Flaig, Thomas W.Mar, NataliyaMoon, Helen H.Friedlander, Terence W.McKay, Rana R.Bilen, Mehmet A.Srinivas, SandyBurgess, Earle F.Ramamurthy, ChethanGeorge, SabyGeynisman, Daniel M.Bracarda, SergioBorchiellini, DelphineGeoffrois, LionnelRey, Jose Pablo MarotoFerrario, ChristianoCarret, Anne-SophieYu, YaoGuseva, MariaMoreno, Blanca HometRosenberg, Jonathan E.
- [2] FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial CarcinomaCLINICAL CANCER RESEARCH, 2024, 30 (10) : 2011 - 2016Maguire, William F.Lee, DanielWeinstock, ChanaGao, XinBulik, Catharine C.Agrawal, SundeepChang, ElaineHamed, Salaheldin S.Bloomquist, Erik W.Tang, ShenghuiPazdur, RichardKluetz, Paul G.Amiri-Kordestani, LalehSuzman, Daniel L.
- [3] New option for cisplatin-ineligible urothelial cancerLANCET ONCOLOGY, 2017, 18 (11): : 1428 - 1430Dreicer, Robert
- [4] Patient Experiences Before and After Enfortumab Vedotin Neoadjuvant Treatment in Cisplatin-Ineligible Muscle-Invasive Bladder CancerVALUE IN HEALTH, 2022, 25 (12) : S400 - S400Flaig, T.Hepp, Z.Narayanan, S.Whyte, J.Johnson, N.Matsuda, T.Hoimes, C.
- [5] BUDGET IMPACT ANALYSIS OF PEMBROLIZUMAB PLUS ENFORTUMAB VEDOTIN AS FIRST-LINE TREATMENT OF CISPLATIN-INELIGIBLE LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN USAVALUE IN HEALTH, 2023, 26 (06) : S88 - S88Lai, Y.Guo, H.Arku, D.Meng, Y.Li, H.
- [6] Enfortumab Vedotin in urothelial cancerTHERAPEUTIC ADVANCES IN UROLOGY, 2020, 12Alt, MarieStecca, CarlosTobin, SwaneeJiang, Di MariaSridhar, Srikala S.
- [7] Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancerLANCET, 2017, 389 (10064): : 6 - +Faltas, Bishoy M.Tagawa, Scott T.
- [8] Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 569 - 569Vlachou, EvangeliaJohnson, Burles AvnerElias, RoyHahn, Noah M.Mcconkey, David JamesHoffman-Censits, Jean H.Hoffman-Censits, Jean H.
- [9] Pembrolizumab plus enfortumab vedotin in urothelial cancerNATURE REVIEWS UROLOGY, 2024, 21 (07) : 387 - 388Santoni, MatteoTakeshita, HidekiMassari, FrancescoBamias, AristotelisCerbone, LindaFiala, OndrejMollica, VeronicaButi, SebastianoSantoni, AngelaBellmunt, Joaquim
- [10] Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (12) : 1403 - 1414Milowsky, Matthew I.O'Donnell, Peter H.Hoimes, Christopher J.Petrylak, Daniel P.Flaig, Thomas W.Moon, Helen H.Friedlander, Terence W.Mar, NataliyaMcKay, Rana R.Srinivas, SandyGravis, GwenaelleRamamurthy, ChethanBupathi, ManojkumarBracarda, SergioWright, PhoebeHepp, ZsoltCarret, Anne-SophieYu, YaoDillon, RyanKataria, RiteshBeaumont, Jennifer L.Purnajo, IntanRosenberg, Jonathan E.